Attralus
Overview
Attralus Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies and diagnostics for systemic amyloidosis, a group of rare and often fatal diseases characterized by the accumulation of amyloid fibrils in tissues and organs. Founded by experts in the field of amyloidosis, Attralus is headquartered in Burlingame, California. The company has gained attention for its proprietary pan-amyloid removal (PAR) therapeutics aimed at treating and potentially reversing various types and stages of systemic amyloidosis.
Recent Developments
- August 2024: Attralus's 124I-evuzamitide (AT-01), a diagnostic imaging agent for cardiac amyloidosis, received Breakthrough Therapy Designation from the U.S. FDA. This designation is based on clinical trials involving over 200 participants and highlights the agent's potential to improve diagnosis for a condition lacking in effective diagnostic tools.
- July 2024: The European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products granted AT-02 positive opinions for orphan medicinal product designations for transthyretin-associated and immunoglobulin light-chain-associated amyloidosis. AT-02 is recognized for its potential as a therapeutic for systemic amyloidosis.
- May 2024: At the XIX International Symposium on Amyloidosis, Attralus presented new data on its therapeutic and diagnostic candidates, highlighting the diagnostic sensitivity and therapeutic potential of AT-01 and AT-02.
- February 2024: Attralus secured $56 million in financing to advance its investigational drugs, including AT-02, which is undergoing Phase I and Phase II trials.
- December 2023: Attralus announced a successful Phase II open-label extension trial of AT-02, showing promising results in amyloid removal and organ function improvement among patients.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | Not publicly specified |
| Headquarters | Burlingame, California, USA |
| Founders | Scientific experts in amyloidosis |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | venBio Partners, others |
| Industry | Biopharmaceuticals |
| Number of Employees | Not publicly disclosed |
Early History
Attralus was founded by experts with a strong background in amyloidosis research. The company was established with the aim of addressing significant unmet needs in the diagnosis and treatment of systemic amyloidosis. Leveraging their expertise in protein misfolding diseases, the founders developed cutting-edge technologies for pan-amyloid removal (PAR), seeking to revolutionize the treatment landscape. Initial funding was secured through a Series A round, which allowed the company to advance their research and enter clinical trials for both diagnostic imaging and therapeutic agents.
Company Profile and Achievements
Attralus's business model focuses on creating novel therapies and diagnostic tools specifically for amyloidosis. The proprietary pan-amyloid removal (PAR) technology underpins the company’s efforts to not only slow disease progression but also actively remove toxic amyloid deposits. Major achievements include:
- Development of AT-01: A diagnostic agent, 124I-evuzamitide, which utilizes pan-amyloid binding peptides to detect amyloid deposits via PET imaging. It has shown efficacy in various clinical trials.
- AT-02 Therapeutic Advances: Employing PAR technology, this candidate has demonstrated potential in removing amyloid deposits in multiple organs, aiming at being a first-in-class disease-modifying treatment.
- Regulatory Recognitions: Receiving orphan drug designations and breakthrough therapy designations from both U.S. and European regulators emphasizes Attralus’s impact in the field.
Current Operations and Market Position
Attralus is actively engaged in clinical trials for its lead candidates, with a robust pipeline that includes AT-01, a diagnostic imaging agent, and AT-02, a pan-amyloid removal therapeutic. The company is strategically positioned within the niche market of systemic amyloidosis, offering a competitive edge through its unique approach in amyloid-related diseases. This focus allows Attralus to target a significantly underserved market, potentially leading to pioneering treatments and diagnostics in the field.
Conclusion
Attralus plays a pivotal role in the biopharmaceutical industry by focusing its efforts on systemic amyloidosis, a group of complex and challenging diseases. With ongoing advancements in their product pipeline and recent regulatory designations, Attralus is poised to make substantial contributions toward improving patient outcomes. As the company progresses through clinical trials, its commitment to innovation suggests a promising future in the field of amyloid-related disorders.